Journal article
Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD
KV Papp, R Buckley, E Mormino, P Maruff, VL Villemagne, CL Masters, KA Johnson, DM Rentz, RA Sperling, RE Amariglio
Alzheimer S and Dementia | WILEY | Published : 2020
Open access
Abstract
Introduction: Demonstrating the “clinical meaningfulness” of slowing early cognitive decline in clinically normal (CN) older adults with elevated amyloid-β (Aβ+) is critical for Alzheimer's disease secondary prevention trials and for understanding early cognitive progression. Methods: Cox regression analyses were used to determine whether 3-year slopes on the preclinical Alzheimer's cognitive composite predicted MCI diagnosis and global Clinical Dementia Rating>0 in 267 Aβ+ CN individuals participating in the Harvard Aging Brain Study, Australian Imaging, Biomarker and Lifestyle Study, and Alzheimer's Disease Neuroimaging Initiative. Results: Steeper preclinical Alzheimer's cognitive composi..
View full abstractGrants
Awarded by Eisai
Funding Acknowledgements
National Institute on Aging, Grant/Award Number: P01AG036694; NIA, Grant/Award Number: 1K23AG053422-01; Alzheimer's Association; Alzheimer's Disease Neuroimaging Initiative; National Institutes of Health, Grant/Award Number: AG024904; DOD, Grant/Award Number: W81XWH-12-2-0012; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; Eisai Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; Canadian Institutes of Health Research; Australian Commonwealth Scientific Industrial and research Organization; Edith Cowan University; Mental Health Research Institute; Alzheimer's Australia; Hollywood Private Hospital; National Health and Medical Research Council; Science and Industry Endowment Fund